Celgene Will Take Barr To Court Over Thalomid Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr filed an ANDA for thalidomide for erythema nodosum leprosum, although Celgene markets the drug more broadly for multiple myeloma.